The company has transitioned to a pre-revenue state with zero revenue reported since 2024Q1, while operating losses expanded to $14.9 million in 2026Q1 due to rising R&D expenditures.
| Sales/Revenue | 0 | 0 | 0 | 0 | 25.9M | 31.42M | 29.32M |
| Revenue Growth % | - | - | - | -100% | -17.56% | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 2.78M | 2.37M | 0 |
| COGS % of Revenue | - | - | - | - | 10.73% | 7.54% | - |
| Gross Profit | 0 | 0 | 0 | 0 | 23.12M | 29.05M | 29.32M |
| Gross Margin % | - | - | - | - | 89.27% | 92.46% | 100% |
| Gross Profit Growth % | - | - | - | -100% | -20.41% | - | - |
| Operating Expenses | 45.59M | 38.6M | 14.1M | 11.87M | 66.6M | 80.88M | 61.12M |
| OpEx % of Revenue | - | - | - | - | 257.11% | 257.44% | 208.43% |
| Selling, General & Admin | 17.48M | 15.76M | 5.94M | 3.08M | 16.38M | 16.68M | 16.9M |
| SG&A % of Revenue | - | - | - | - | 63.25% | 53.1% | 57.62% |
| Research & Development | 28.1M | 22.84M | 8.15M | 8.79M | 50.21M | 64.2M | 44.22M |
| R&D % of Revenue | - | - | - | - | 193.85% | 204.33% | 150.8% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -45.59M | -38.6M | -14.1M | -11.87M | -43.47M | -51.83M | -33.92M |
| Operating Margin % | - | - | - | - | -167.84% | -164.97% | -115.68% |
| Operating Income Growth % | - | -173.87% | -18.75% | 72.7% | 16.12% | - | - |
| EBITDA | -33.95M | -35.9M | -13.12M | 18.69M | -40.69M | -49.46M | -31.79M |
| EBITDA Margin % | - | - | - | - | -157.11% | -157.44% | -108.43% |
| EBITDA Growth % | -109.78% | -173.67% | -170.18% | 145.93% | 17.73% | - | - |
| D&A (Non-Cash Add-back) | 10.18M | 0 | 0 | 0 | 2.78M | 2.37M | 2.13M |
| EBIT | -43.78M | -35.9M | -13.12M | 18.69M | -33.28M | -45.74M | -37.07M |
| Net Interest Income | -726K | -3.23M | -4.32M | 6.26M | 721K | 4K | 511K |
| Interest Income | 1.84M | 2.59M | 0 | 6.26M | 721K | 4K | 511K |
| Interest Expense | 2.56M | 5.82M | 4.32M | 0 | 0 | 0 | 0 |
| Other Income/Expense | -3.71M | -3.11M | -3.34M | 30.56M | 10.2M | 6.09M | -3.15M |
| Pretax Income | -49.3M | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M | -37.07M |
| Pretax Margin % | - | - | - | - | -128.47% | -145.58% | -126.41% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 164K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | -0.44% |
| Net Income | -49.3M | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M | -37.23M |
| Net Margin % | - | - | - | - | -128.47% | -145.58% | -126.97% |
| Net Income Growth % | -161.61% | -139.27% | -193.27% | 156.17% | 27.24% | - | - |
| Net Income (Continuing) | -49.3M | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M | -37.23M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.77 | -3.71 | -7.83 | 14.74 | -29.61 | -56.69 | -54.67 |
| EPS Growth % | 58.01% | 52.62% | -153.12% | 149.78% | 47.77% | - | - |
| EPS (Basic) | - | -3.71 | -7.83 | 14.74 | -29.61 | -56.69 | -54.67 |
| Diluted Shares Outstanding | 13.09M | 11.25M | 2.23M | 1.27M | 930.35K | 806.84K | 681.01K |
| Basic Shares Outstanding | 13.09M | 11.25M | 2.23M | 1.27M | 930.35K | 806.84K | 681.01K |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Clinical trial funding dependency
As indicated by the most recent quarterly financial filings, Palvella Therapeutics has transitioned to a pre-revenue state, with zero revenue reported since 2024Q1, underscoring the company's total reliance on the successful advancement of its clinical-stage pipeline rather than current commercial product sales or recurring income streams.
The lack of top-line growth is a direct consequence of the company's strategic pivot toward Phase 3 clinical development for its lead candidate. Investors should interpret this as a binary risk profile where future revenue generation is entirely contingent upon regulatory approval and successful market entry.
Based on the reported income statement data, R&D expenses have climbed steadily from $984,000 in 2024Q1 to $9.3 million in 2026Q1, reflecting the intensifying capital requirements associated with late-stage clinical trial site management and patient recruitment for the company's primary therapeutic programs.
This upward trend in R&D spending suggests that the company is nearing a critical juncture in its clinical timeline. The consistent expansion of these costs warrants close monitoring, as they represent the primary driver of the company's widening net losses and ongoing cash consumption.
According to the provided financial statements, the company's operating loss has expanded significantly to $14.9 million in 2026Q1, a trend that highlights the absence of operating leverage as the firm continues to prioritize clinical development milestones over achieving a sustainable or profitable operating structure.
The widening gap between R&D investment and the lack of revenue indicates that the company is currently in a phase of maximum capital intensity. Without a commercial product to offset these fixed costs, the firm remains highly sensitive to any delays in its regulatory pathway.
As reported in recent financial disclosures, the company's net loss reached $15.8 million in 2026Q1, a figure that raises concerns regarding the sustainability of its current cash runway given the $57.9 million cash balance and the absence of any meaningful revenue-generating activities to mitigate losses.
Short-term observers may focus on the potential for dilutive financing if clinical timelines extend beyond current projections. The lack of a diversified revenue base makes the company particularly vulnerable to market volatility and the high cost of capital inherent in the biotechnology sector.
Quick answers to the most common questions about buying PVLA stock.
For fiscal year 2025, Palvella Therapeutics, Inc. (PVLA) reported total revenue of $0.0M. This represents a 100.0% decline compared to $29.3M in 2020.
Palvella Therapeutics, Inc. (PVLA) reported a net loss of $41.7M for the fiscal year ending 2025.